General Cardiology
Myocarditis diagnosis, treatment, and outcomes
Also called viral myocarditis, inflammatory cardiomyopathy
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Myocarditis involves inflammatory processes of the muscular walls of the heart that result in injury to cardiac myocytes.1
Diagnosis is often difficult due to variable clinical presentations.1 Cardiac biomarkers and multimodality imaging are frequently used as initial diagnostic tests.1 Classic findings on cardiovascular magnetic resonance include increased native T1 and T2 signals, which can indicate inflammation, edema, or fibrosis.2 However, the accuracy of conventional biomarkers and advanced imaging is reduced in patients with systemic autoimmune rheumatic diseases due to chronic inflammation.3 An endomyocardial biopsy is required for a definitive diagnosis of giant cell myocarditis.1 In contrast, endomyocardial biopsy is not advocated to diagnose myocarditis in the setting of COVID-19.4 Myocarditis is an uncommon pathologic diagnosis occurring in 4.5% of highly selected cases undergoing autopsy or endomyocardial biopsy.4
The management of giant cell myocarditis involves a combination of immunosuppressive therapy and guideline-directed medical therapy, which has improved overall and transplant-free survival.1 For myocarditis associated with immune checkpoint inhibitors, treatment typically includes corticosteroids and the discontinuation of the offending therapy.2 Refractory cases of immune checkpoint inhibitor myocarditis have benefited from plasmapheresis, intravenous immunoglobulin, mycophenolate, tacrolimus, or infliximab.2 In patients with systemic autoimmune rheumatic diseases, the management of myopericardial involvement primarily targets the underlying rheumatic condition.3
There are unknown rates of adverse outcomes associated with exercise resumption following SARS-CoV-2 infection and associated myocarditis.1
Suppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway
Journal of Cardiovascular Translational Research — Liu Y — Sep 2026
Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases
The Lancet Rheumatology — Plein S — Sep 2026
Development of a universal primer set for the identification of enterovirus serotypes using next-generation sequencing
Legal Medicine — Shionoya K — Sep 2026
Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports
Cancer Reports — Godin S — Sep 2026
Racial and Ethnic Disparities in Acute Myocarditis Outcomes in the United States
Clinical Cardiology — Osorio M — Aug 2026
Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System
Cancer Medicine — Chen T — Aug 2026
H4K5 lactylation exacerbates acute myocarditis by driving a positive feedback loop between inflammation and metabolic dysfunction
Frontiers in Immunology — Zhao Y — Aug 2026
Giant cell myocarditis: from immune pathogenesis to contemporary management
Heart Failure Reviews — Vosko I — Aug 2026
Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals
Vaccine — Toraih E — Aug 2026
Evaluating the reliability and quality of viral myocarditis educational content on TikTok and Bilibili
Medicine — Zhu Z — Aug 2026
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play
Journal of the American College of Cardiology — Gluckman T
486 citations · 2022 · among the most cited on Myocarditis
Pathophysiology of Takotsubo Syndrome
Journal of the American College of Cardiology — Lyon A
429 citations · 2021 · among the most cited on Myocarditis
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis
Journal of the American College of Cardiology — Kawakami R
241 citations · 2021 · among the most cited on Myocarditis
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Journal of the American College of Cardiology — Thavendiranathan P
227 citations · 2021 · among the most cited on Myocarditis
Management of Patients With Giant Cell Myocarditis
Journal of the American College of Cardiology — Bang V
123 citations · 2021 · among the most cited on Myocarditis
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.